Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
In the Omicron BA.5 variant, there were also 546 (53.2%) male and 480 (46.8%) female patients.Comparison of laboratory parameters between SARS-CoV-2 variantsSARS-CoV-2 variantsVariablesAlpha (n = 1,022)Delta (n = 1,026)Omicron BA.5 (n = 1,136)P-valueDeceased/ Improved patients479/543 (46.9/53.1%)674/352 (65.7/34.3%)297/839 (26.1/73.9%) < 0.001*Mean age ± SD53.0 ± 12.758.0 ± 11.853.7 ± 12.90.128Gender (male/female)525/497(51.4/48.6%)546/480 (53.2/46.8%)598/538 (52.6/47.4%)0.692ALT, IU/L (mean ± SD) (Reference range: 5 to 40)38.5 ± 24.840.8 ± 24.735.8 ± 24.20.001AST, IU/L (mean ± SD) (Reference range: 5 to 40)34.9 ± 15.534.5 ± 14.031.9 ± 14.4 < 0.001*ALP, IU/L (mean ± SD) (Reference range: up to 306)190.2 ± 84.7188.6 ± 74.0177.2 ± 83.5 < 0.001*Cholesterol, mg/dL (mean ± SD) (Reference range: 50 to 200)116.1 ± 34.1120.5 ± 40.5123.1 ± 39.4 < 0.001*TG, mg/dL (mean ± SD) (Reference range: 60 to 165)124.1 ± 54.9121.6 ± 48.8126.9 ± 55.90.245LDL, mg/dL (mean ± SD) (Reference range: up to 150)82.8 ± 45.185.3 ± 45.3104.7 ± 48.3 < 0.001*HDL, mg/dL (mean ± SD) (Reference range: > 40)32.5 ± 11.332.1 ± 11.533.6 ± 11.70.039*WBC, 109/L (mean ± SD) (Reference range: 4000 to 10,000)7627.3 ± 2843.27599.2 ± 2715.77704.9 ± 2807.70.297CRP, mg/L (mean ± SD) (Reference range: < 10 mg/L Negative)61.6 ± 21.563.9 ± 22.060.2 ± 21.70.122ESR, mm/1st h (mean ± SD) (Reference range: 0 to 15)50.1 ± 16.052.3 ± 16.049.1 ± 16.10.025FBS, mg/dL (mean ± SD) (Reference range: 70 to 100)107.1 ± 41.6109.8 ± 43.2106.5 ± 40.70.716Platelets × 1000/cumm (mean ± SD) (Reference range: 140,000 to 400,000)184 ± 71185 ± 74184 ± 690.994Uric acid, mg/dL (mean ± SD) (Reference range: 3.6 to 6.8)4.8 ± 1.84.4 ± 1.75.2 ± 1.8 < 0.001*Creatinine, mg/dL (mean ± SD) (Reference range: 0.6 to 1.4)0.9 ± 0.31.0 ± 0.30.8 ± 0.3 < 0.001*qPCR Ct value20.1 ± 6.417.4 ± 6.121.9 ± 6.0 < 0.001*25-hydroxy vitamin D, ng/mL (mean ± SD) (Sufficiency: 21 to 150)24.2 ± 12.821.8 ± 10.333.0 ± 13.40.029*IL10 rs1800871 < 0.001*TT271 (26.5%)498 (48.5%)391 (34.4%)CT550 (53.8%)377 (36.7%)619 (54.5%)CC201 (19.7%)151 (14.8%)126 (11.1%)IL10 rs1800872 < 0.001*GG474 (46.4%)532 (51.9%)269 (23.7%)GT396 (38.7%)386 (37.6%)711 (62.6%)TT152 (14.9%)108 (10.5%)156 (13.7%)IL10 rs1800896 < 0.001*AA358 (35.0%)510 (49.7%)575 (50.6%)AG550 (53.8%)338 (32.9%)511 (45.0%)GG114 (11.2%)178 (17.4%)50 (4.4%)ALT Alanine aminotransferase, AST Aspartate aminotransferase, ALP Alkaline phosphatase, TG Triglyceride, LDL Low density lipoprotein, HDL High density lipoprotein, WBC White blood cells, CRP C-reactive protein, ESR Erythrocyte sedimentation rate, FBS Fasting blood glucose, SD Standard deviation, SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2, IL10 interleukins 10. *Statistically significant (< 0.05)
Source: Demographics and baseline clinical characteristics of COVID-19 patients. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
According to the World Health Organization guidelines, adult COVID-19 patients were divided into three clinical course categories, mild, moderate, and severe.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Association between interleukin-10 gene polymorphisms (rs1800871, rs1800872, and rs1800896) and severity of infection in different SARS-CoV-2 variants
Study design awaiting verification · Human Genomics · 2023
Original publication title
Association between interleukin-10 gene polymorphisms (rs1800871, rs1800872, and rs1800896) and severity of infection in different SARS-CoV-2 variants
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Polymorphisms in the interleukin-10 (IL10) gene have been linked to the severity of the patients infected with the viral infections. This study aimed to assess if the IL10 gene polymorphisms rs1800871, rs1800872, and rs1800896 were linked to coronavirus disease 19 (COVID-19) mortality in different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in the Iranian population.
Source: BackgroundAbstract: What methods does the paper describe?
For genotyping IL10 rs1800871, rs1800872, and rs1800896, this study used the polymerase chain reaction-restriction fragment length polymorphism method in 1,734 recovered and 1,450 deceased patients.
Source: MethodsAbstract: Results
The obtained finding indicated IL10 rs1800871 CC genotype in the Alpha variant and CT genotype in the Delta variant had a relationship with COVID-19 mortality; however, there was no association between rs1800871 polymorphism and the Omicron BA.5 variant. The COVID-19 mortality rate was associated with IL10 rs1800872 TT genotype in the Alpha and Omicron BA.5 variants and GT in the Alpha and Delta variants. The COVID-19 mortality rate was associated with IL10 rs1800896 GG and AG genotypes in the Delta and Omicron BA.5; nevertheless, there was no association between rs1800896 polymorphism with the Alpha variant.
According to the obtained data, the GTA haplotype was the most common of haplotype in different SARS-CoV-2 variants. The TCG haplotype was related to COVID-19 mortality in the Alpha, Delta and Omicron BA.5 variants.
Source: ResultsAbstract: Conclusion
The IL10 polymorphisms had an impact on COVID-19 infection, and these polymorphisms had different effects in various SARS-CoV-2 variants. To verify the obtained results, further studies should be conducted on various ethnic groups.
Source: ConclusionAuthors’ abstract
Background
Polymorphisms in the interleukin-10 (IL10) gene have been linked to the severity of the patients infected with the viral infections. This study aimed to assess if the IL10 gene polymorphisms rs1800871, rs1800872, and rs1800896 were linked to coronavirus disease 19 (COVID-19) mortality in different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in the Iranian population.
Methods
For genotyping IL10 rs1800871, rs1800872, and rs1800896, this study used the polymerase chain reaction-restriction fragment length polymorphism method in 1,734 recovered and 1,450 deceased patients.
Results
The obtained finding indicated IL10 rs1800871 CC genotype in the Alpha variant and CT genotype in the Delta variant had a relationship with COVID-19 mortality; however, there was no association between rs1800871 polymorphism and the Omicron BA.5 variant. The COVID-19 mortality rate was associated with IL10 rs1800872 TT genotype in the Alpha and Omicron BA.5 variants and GT in the Alpha and Delta variants. The COVID-19 mortality rate was associated with IL10 rs1800896 GG and AG genotypes in the Delta and Omicron BA.5; nevertheless, there was no association between rs1800896 polymorphism with the Alpha variant.
According to the obtained data, the GTA haplotype was the most common of haplotype in different SARS-CoV-2 variants. The TCG haplotype was related to COVID-19 mortality in the Alpha, Delta and Omicron BA.5 variants.
Conclusion
The IL10 polymorphisms had an impact on COVID-19 infection, and these polymorphisms had different effects in various SARS-CoV-2 variants. To verify the obtained results, further studies should be conducted on various ethnic groups.
Publication and source details
Original title: Association between interleukin-10 gene polymorphisms (rs1800871, rs1800872, and rs1800896) and severity of infection in different SARS-CoV-2 variants
Sattar Jabbar Abbood Abbood; Enayat Anvari; Abolfazl Fateh
Human Genomics · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T20:11:04.965639+00:00
DOI: 10.1186/s40246-023-00468-6 · PMC9990970